Logo
x

Search

Subscribe Now

MediciNova

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) for the Post-COVID Condition

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) for the Post-COVID Condition

  • August 30, 2024
The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Multiple Solid Tumors

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Multiple Sol...

  • June 5, 2024
The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer

The USPTO Issues Notice of Allowance for New Patent Covering MediciNova’s Ibudilast (MN-166) to Prevent Metastasis of Eye Cancer

  • May 20, 2024
MediciNova Presenting New Data from the P-II Study of MN-166 (ibudilast) at Annual Meeting of the Society for Neuro-Oncology

MediciNova Presenting New Data from the P-II Study of MN-166 (ibudilast) at Annual Meeting of the Society for Neuro-Oncology

  • November 20, 2023
MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma

MediciNova Reports the Completion of Patient Enrollment in the P-II Clinical Trial of MN-166 (ibudilast) for Glioblastoma

  • January 13, 2023
Insights+: COVID-19 Healthcare News Monthly Updates - July 2020

Insights+: COVID-19 Healthcare News Monthly Updates - July 2020

  • July 31, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.